TABLE 3

Adherence to pulmonary hypertension-specific treatment

	All			PAH			CTEPH
	Number included	% Adherence (NoDC)	% Adherence (Man)	Number included	% Adherence (NoDC)	% Adherence (Man)	Number included	% Adherence (NoDC)	% Adherence (Man)
ERA
Ambrisentan	99	87	83	90	87	82	9	89	89
Bosentan	98	71	66	73	71	68	25	72	60
Macitentan	166	84	78	146	82	77	20	95	90
PDE-5i
Sildenafil	207	60	61	146	61	62	61	59	59
Tadalafil	137	80	74	117	80	74	20	80	75
SGCs
Riociguat	32	91	91	2	0	0	30	90	90
Single treatment	209	68	65	131	69	66	78	67	63
Double treatment	234	64	59	198	64	58	36	67	67
Oral^#+PRO	66	74	70	60	73	70	6	83	83

Data are presented as number of patients who filled a prescription and were included in the analyses, and proportion of those with good adherence shown for Number of days covered (NoDC) and Manual assessment (Man) methods. PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; ERA: Endothelin receptor antagonists; PDE-5i: Phosphodiesterase type 5 inhibitors; SGCs: Soluble guanylate cyclase stimulator; PRO: prostacyclin therapy. ^#: Adherence to oral treatment reported.